NASDAQ:INCY Incyte (INCY) Stock Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free INCY Stock Alerts $51.68 +0.50 (+0.98%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$50.87▼$51.8550-Day Range$51.18▼$61.0052-Week Range$50.27▼$75.74Volume1.56 million shsAverage Volume1.72 million shsMarket Capitalization$11.60 billionP/E Ratio19.50Dividend YieldN/APrice Target$75.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Incyte alerts: Email Address Incyte MarketRank™ Stock AnalysisAnalyst RatingHold2.44 Rating ScoreUpside/Downside46.1% Upside$75.50 Price TargetShort InterestBearish3.68% of Shares Sold ShortDividend StrengthN/ASustainability-2.66Upright™ Environmental ScoreNews Sentiment0.39Based on 28 Articles This WeekInsider TradingN/AProj. Earnings Growth24.94%From $3.85 to $4.81 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.82 out of 5 starsMedical Sector45th out of 908 stocksCommercial Physical Research Industry3rd out of 11 stocks 4.2 Analyst's Opinion Consensus RatingIncyte has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 7 buy ratings, 9 hold ratings, and no sell ratings.Amount of Analyst CoverageIncyte has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.68% of the outstanding shares of Incyte have been sold short.Short Interest Ratio / Days to CoverIncyte has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Incyte has recently increased by 2.61%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIncyte does not currently pay a dividend.Dividend GrowthIncyte does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIncyte has received a 38.38% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Janus-associated kinase (JAK) inhibitors", "Ponatinib", and "Tafasitamab" products. See details.Environmental SustainabilityThe Environmental Impact score for Incyte is -2.66. Previous Next 1.9 News and Social Media Coverage News SentimentIncyte has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 28 news articles for Incyte this week, compared to 8 articles on an average week.Search InterestOnly 14 people have searched for INCY on MarketBeat in the last 30 days. This is a decrease of -7% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is a decrease of -78% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Incyte insiders have not sold or bought any company stock.Percentage Held by Insiders17.50% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.97% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Incyte are expected to grow by 24.94% in the coming year, from $3.85 to $4.81 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Incyte is 19.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.98.Price to Earnings Ratio vs. SectorThe P/E ratio of Incyte is 19.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 197.91.Price to Earnings Growth RatioIncyte has a PEG Ratio of 1.20. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIncyte has a P/B Ratio of 2.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. About Incyte Stock (NASDAQ:INCY)Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.Read More INCY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INCY Stock News HeadlinesApril 26, 2024 | seekingalpha.comIncyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)April 26, 2024 | americanbankingnews.comQ1 2025 Earnings Forecast for Incyte Co. (NASDAQ:INCY) Issued By William BlairApril 26, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 25, 2024 | americanbankingnews.comIncyte Co. (NASDAQ:INCY) to Post Q2 2025 Earnings of $1.19 Per Share, William Blair ForecastsApril 24, 2024 | americanbankingnews.comIncyte (NASDAQ:INCY) Now Covered by Analysts at Cantor FitzgeraldApril 23, 2024 | markets.businessinsider.comPeeling Back The Layers: Exploring Incyte Through Analyst InsightsApril 23, 2024 | markets.businessinsider.comIncyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst RecommendsApril 23, 2024 | marketwatch.comIncyte to Buy Escient Pharmaceuticals for $750 MillionApril 26, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 23, 2024 | markets.businessinsider.comIncyte To Buy Privately Held Escient PharmaApril 23, 2024 | bizjournals.comIncyte to acquire San Diego pharma firm in $750 million dealApril 23, 2024 | businesswire.comIncyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR AntagonistsApril 23, 2024 | americanbankingnews.comIncyte (INCY) Scheduled to Post Earnings on TuesdayApril 20, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for Incyte Co. Increased by William Blair (NASDAQ:INCY)April 15, 2024 | finance.yahoo.comThe past three years for Incyte (NASDAQ:INCY) investors has not been profitableApril 11, 2024 | businesswire.comIncyte to Report First Quarter Financial ResultsApril 9, 2024 | bloomberg.comPublic Markets Are the New Private MarketsApril 9, 2024 | msn.comBay Area exec loses groundbreaking 'shadow trading' trialApril 6, 2024 | finance.yahoo.comBiotech Executive Who Bet on Rival’s Stock Committed Insider Trading, Jury SaysApril 1, 2024 | markets.businessinsider.comCMS To Receive License To Develop, Commercialize Povorcitinib In China And Southeast AsiaApril 1, 2024 | finance.yahoo.comIncyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast AsiaApril 1, 2024 | globenewswire.comCMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast AsiaMarch 29, 2024 | businesswire.comIncyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 26, 2024 | finance.yahoo.comSEC Tests Insider-Trading Theory at Trial of Ex-Biotech ExecutiveMarch 25, 2024 | finance.yahoo.comJean-Jacques Bienaimé Appointed Chairman of the Board at OwkinMarch 25, 2024 | markets.businessinsider.comRBC Capital Sticks to Its Hold Rating for Incyte (INCY)March 13, 2024 | markets.businessinsider.comIncyte’s Hold Rating: Balancing Clinical Promise Against Financial and Market PositionSee More Headlines Receive INCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2024Today4/26/2024Next Earnings (Confirmed)4/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryBiotechnology Current SymbolNASDAQ:INCY CUSIP45337C10 CIK879169 Webwww.incyte.com Phone(302) 498-6700Fax302-425-2750Employees2,524Year Founded1991Price Target and Rating Average Stock Price Target$75.50 High Stock Price Target$93.00 Low Stock Price Target$64.00 Potential Upside/Downside+46.1%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)$2.65 Trailing P/E Ratio19.50 Forward P/E Ratio13.42 P/E Growth1.2Net Income$597.60 million Net Margins16.17% Pretax Margin22.57% Return on Equity12.56% Return on Assets9.64% Debt Debt-to-Equity Ratio0.01 Current Ratio3.55 Quick Ratio3.36 Sales & Book Value Annual Sales$3.70 billion Price / Sales3.14 Cash Flow$2.43 per share Price / Cash Flow21.25 Book Value$23.16 per share Price / Book2.23Miscellaneous Outstanding Shares224,530,000Free Float185,234,000Market Cap$11.60 billion OptionableOptionable Beta0.65 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Herve Hoppenot (Age 64)CEO & Chairman Comp: $2.89MMs. Christiana Stamoulis MBA (Age 53)Executive VP & CFO Comp: $1.16MDr. Barry P. Flannelly M.B.A. (Age 66)Pharm.D., Executive VP & GM of North America Comp: $996.28kDr. Steven H. Stein M.D. (Age 57)Executive VP & Chief Medical Officer Comp: $1.22MDr. Pablo J. Cagnoni M.D. (Age 61)Ph.D., President and Head of Research & Development Mr. Thomas Tray (Age 46)VP of Finance, Chief Accounting Officer & Controller Mr. Michael James Morrissey (Age 60)Executive VP & Head of Global Technical Operations Sheila A. Denton (Age 58)Executive VP, General Counsel & Corporate Secretary Ms. Pamela M. Murphy (Age 73)Vice President of Investor Relations & Corporate Communications Ms. Paula J. Swain (Age 66)Executive Vice President of Human Resources Comp: $611.92kMore ExecutivesKey CompetitorsCharles River Laboratories InternationalNYSE:CRLPRA Health SciencesNASDAQ:PRAHMedpaceNASDAQ:MEDPExelixisNASDAQ:EXELPPDNASDAQ:PPDView All CompetitorsInsiders & InstitutionsYousif Capital Management LLCSold 381 shares on 4/26/2024Ownership: 0.010%Mesirow Financial Investment Management Inc.Bought 6,950 shares on 4/26/2024Ownership: 0.003%Zurcher Kantonalbank Zurich Cantonalbank Sold 12,433 shares on 4/25/2024Ownership: 0.144%New York State Teachers Retirement SystemBought 3,739 shares on 4/25/2024Ownership: 0.091%Capital Investment Advisory Services LLCBought 5,580 shares on 4/25/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions INCY Stock Analysis - Frequently Asked Questions Should I buy or sell Incyte stock right now? 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 9 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares. View INCY analyst ratings or view top-rated stocks. What is Incyte's stock price target for 2024? 16 brokers have issued 12-month price targets for Incyte's shares. Their INCY share price targets range from $64.00 to $93.00. On average, they predict the company's stock price to reach $75.50 in the next year. This suggests a possible upside of 46.1% from the stock's current price. View analysts price targets for INCY or view top-rated stocks among Wall Street analysts. How have INCY shares performed in 2024? Incyte's stock was trading at $62.79 on January 1st, 2024. Since then, INCY shares have decreased by 17.7% and is now trading at $51.68. View the best growth stocks for 2024 here. When is Incyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024. View our INCY earnings forecast. How can I listen to Incyte's earnings call? Incyte will be holding an earnings conference call on Tuesday, April 30th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13745743". How were Incyte's earnings last quarter? Incyte Co. (NASDAQ:INCY) issued its quarterly earnings data on Tuesday, February, 13th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, missing analysts' consensus estimates of $1.15 by $0.09. The biopharmaceutical company had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. Incyte had a trailing twelve-month return on equity of 12.56% and a net margin of 16.17%. The firm's quarterly revenue was up 9.3% compared to the same quarter last year. During the same period last year, the firm earned $0.44 EPS. Read the conference call transcript. What ETFs hold Incyte's stock? ETFs with the largest weight of Incyte (NASDAQ:INCY) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust NYSE Arca Biotechnology Index Fund (FBT), Tema Oncology ETF (CANC), IQ U.S. Mid Cap R&D Leaders ETF (MRND), ASYMshares ASYMmetric S&P 500 ETF (ASPY), VanEck Biotech ETF (BBH), Strategas Global Policy Opportunities ETF (SAGP) and Virtus LifeSci Biotech Products ETF (BBP). What is Hervé Hoppenot's approval rating as Incyte's CEO? 22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees. What other stocks do shareholders of Incyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA). Who are Incyte's major shareholders? Incyte's stock is owned by a variety of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.69%), Sumitomo Mitsui Trust Holdings Inc. (0.28%), Assenagon Asset Management S.A. (0.26%), Allspring Global Investments Holdings LLC (0.18%), Zurcher Kantonalbank Zurich Cantonalbank (0.14%) and New York State Teachers Retirement System (0.09%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Jonathan Elliott Dickinson, Maria E Pasquale, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing. View institutional ownership trends. How do I buy shares of Incyte? Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INCY) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlaceBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.